FY2017 EPS Estimates for Oncolytics Biotech Inc. (TSE:ONC) Decreased by Analyst
Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at Zacks Investment Research dropped their FY2017 EPS estimates for shares of Oncolytics Biotech in a report released on Tuesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.12) for the year, down from their previous estimate of ($0.11).
Several other analysts have also recently issued reports on ONC. Royal Bank Of Canada boosted their price objective on shares of Oncolytics Biotech from C$1.00 to C$1.50 and gave the company an “outperform” rating in a research note on Thursday, April 13th. BMO Capital Markets boosted their price objective on shares of Oncolytics Biotech from C$1.00 to C$1.50 and gave the company an “outperform” rating in a research note on Thursday, April 13th.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Oncolytics Biotech Inc. (TSE:ONC) Decreased by Analyst” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/10/fy2017-eps-estimates-for-oncolytics-biotech-inc-tseonc-decreased-by-analyst.html.
Oncolytics Biotech (ONC) opened at 0.51 on Thursday. The firm’s market capitalization is $62.14 million. The company has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.57. Oncolytics Biotech has a 12-month low of $0.19 and a 12-month high of $1.13.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies.
Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.